Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.

A subgroup analysis of patients with PMF, post-PV-MF, or post-ET-MF showed that in all of these subgroups, a low platelet count might be a mild risk factor for major bleeding events but this did not reach statistical significance (data not shown).

also in 111,027 other papers

P2Y12 antagonists as well as double-agent antiplatelet therapy narrowly missed the significance level, possibly due to small sample size (27 and 20 patients).

also in 8 other papers

The administration of a P2Y12 antagonist or double platelet inhibition showed a positive trend for the latter (Table 5 ).

also in 11,005 other papers